fig2
![Efficacy and HCC development after DAA therapy for patients with chronic hepatitis C: a single center retrospective cohort study](https://image.oaes.cc/837b5ef5-25fe-44fb-8b90-e73773c78a94/2255.fig.2.png)
Figure 2. SVR24 rate with GT1 or GT2. All patients achieved SVR24 regardless of GT1 or GT2. SVR: sustained virological response; DCV: daclatasvir; ASV: asunaprevir; SOF: sofosbuvir; LDV: ledipasvir; RBV: ribavirin
Figure 2. SVR24 rate with GT1 or GT2. All patients achieved SVR24 regardless of GT1 or GT2. SVR: sustained virological response; DCV: daclatasvir; ASV: asunaprevir; SOF: sofosbuvir; LDV: ledipasvir; RBV: ribavirin
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/